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1. Introduction 
Photodynamic therapy (PDT) is a relatively new modality of cancer treatment. Actual 
ongoing clinical era started with the studies of Dougherty in the 1970s. PDT is based on the 
application of a so called photosensitizer (PS), which preferably enriches in the tumor tissue. 
The application of light at an appropriate wavelength excites the PS molecules from their 
ground state S0 to an electronically excited singlet state Sx. The energy of the excited state 
can be dissipated via several relaxation pathways. By this, so called cytotoxic reactive 
oxygen species (ROS) are generated. ROS react with various biomolecules inducing cell 
death by different mechanims.(Dougherty et al. 1998b) 
2. History of PDT 
The newer history of PDT starts with the observations of Von Tappeiner and Raab at the 
Maximilian Ludwig University in Munich. In 1900, Raab first reported on the chemical 
sensitisation of tissue by light.(Raab 1900) Von Tappeiner described in 1904 the so called 
“photodynamic reaction”.(Tappeiner & Jodlbauer 1904) He believed that this effect was 
based on fluorescence. In contrast Neiser (Breslau) and Dreyer (Finsen Institue in 
Kopenhagen) described a sensitisation by light for photodynamic reaction.(Dreyer 
1903;Neisser & Halberstaedtter 1904) At this time Ledoux-Lebards already proved the 
concept of the presence of oxygen as a condition for PDT at the Institute Pasteur in Paris 
(1902).(Ledoux-Lebards 1902) In this era skin diseases were treated with chinidin, acridin 
and eosin with unsatisfying results. 
Already from the beginning of PDT, haematoporphyrin (Hp) was of special interest. 
Hausmann used Hp for photodynamic investigations in mice in 1911.(Hausmann 1911) In 
1913, Meyer-Betz studied Hp to determine its biological effects on himself. After exposition 
to sunlight he suffered from extensive phototoxic reactions.(Meyer-Betz 1913) Policard 
detected 1924 in rat sarcoma a red fluorescence after Hp administration.(Policard 1924) In 
1942 Auler and Banzer reported on the affinity of neoplastic tissues for Hp in tumor, 
metastases and lymphatic vessels in patients suffering cancer.(Auler & Banzer 1942) Further 
investigations were performed by Figge et al. in 1948; they demonstrated the properties of 
Hp to localize tumors.(Figge, Weiland, & Manganiello 1948) Due to high toxic reactions of 
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Hp, in 1955 a hematoporphyrin derivat (HpD) was developed by Schwartz et al..(Schwartz, 
Absolon, & Vermund 1955) This derivat also contained many components of 
hematoporphyrins. Lipson et al. used the HpD in vivo and in patients for tumor detection 
and localisation in the early sixties.(Lipson, Baldes, & Olsen 1964) 
A milestone in PDT was done by Dougherty in 1973.(Dougherty 1973) Dougherty 
postulated the criteria for PSs and for PDT. Essential for a successful PS is less or no toxicity 
without light, selective enrichment in the tumor or affected tissue and activation by light 
with a wavelength of 600 nm or more.(Dougherty et al. 1978;Dougherty et al. 1998a) HpD 
was further purified by Dougherty’s group to Photofrin®. Photofrin is up to now for PDT 
drug approved.  
2.1 First and second generation photosensitizers 
HpD and Photofrin® are first generation PSs. The maximum of absorption of HpD is 628 to 
632 nm. Penetration depth is about 5 mm. In vivo the concentration of HpD is twelve times 
higher compared to normal brain tissue. In clinical investigations the concentration was 
1:2.5 to 1:4 fold. (Kostron, Obwegeser, & Jakober 1996) This first generation PSs have some 
disadvantages, e.g. high impurity, prolonged skin photosensitivity about several weeks and 
low absorbance at 630 nm, where tissue penetration of light is low. To improve this, second 
generation photosensitizers (phthalocyanines, naphthalocyanins, benzoporphyrins, 
chlorines, purpurins, texaphyrins, porphycenes, pheophobides, bacteriochlorins, etc.) were 
introduced (Juzeniene, Peng, & Moan 2007). Second generation PSs have a high absorbance 
in the region of 650-850 nm and produce adequate singlet oxygen. Meta-tetra 
hydroxyphenylchlorin (m-THPC; Foscan®, Biolitec AG) and benzoporphyrin derivative 
monoacid A (BPD-MA; Visudyne®, QLT Inc. and Novartis Opthalmics) are approved drugs 
for clinical use. The second generation PS mTHPC has its maximum absorption at 652 nm. 
Phototoxic reaction had been observed up to a depth of 15 mm. For meta-
tetrahydroxyphenylchlorin (mTHPC) a ratio tumor to normal tissue of more than 80:1 has 
been described in vivo after implantation of C6 glioma in Spraque-Dawley rats. In clinical 
applications the ratio tumor to normal brain tissue was 20:1.(Dougherty, Gomer, Henderson, 
Jori, Kessel, Korbelik, Moan, & Peng 1998a;Obwegeser, Jakober, & Kostron 1998) Several 
more PSs are available, but have been less usage in neurosurgery. Third generation PSs are 
second generation photosensitizers bound to carriers for selective accumulation in the 
tumor. 
2.2 Prodrug: 5-aminolevulinic acid derived protoporphyrin IX 
5-aminolevulinic acid (5-ALA) a prodrug transformed to 5-aminolevulinic acid-derived 
protoporphyrin IX (5-ALA PpIX) is especially used for photodiagnosis (PD) although 
properties for as a PS are known. In 1955 Scott described the transitory hypersensitivity to 
sunlight following exogenous administration of 5-ALA.(Scott 1955) First description about 
the use of 5-ALA as a porphyrin precursor in PDT was done by Malik and Lugaci, who 
demonstrated, that exogenous 5-ALA PpIX in combination with light led to inactivation of 
leukemic cells.(Malik & Lugaci 1987) Kennedy et al. reported about successful treatment of 
malignant and precancerous skin diseases in 1990.(Kennedy, Pottier, & Pross 1990) The use 
of 5-ALA PpIX in neurosurgery for fluorescence guided resection of glioblastoma was a 
milestone. Stummer et al. demonstrated convincingly that the radicality of tumor resection 
and thus the outcome of patients improves significantly by intraoperative tumor 
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visualisation.(Stummer et al. 2000;Stummer et al. 2006;Stummer et al. 2008) 5-ALA is a 
precursor, converted in malignant cells to PpIX, the fluorescent substance. 5-ALA is the first 
substrate in the heme biosynthesis. Heme biosynthesis consists of eight discrete enzymes 
catalysed steps which involve the mitochondrial (the first and the last three steps) and 
cytosolic (the other four intermediate steps) compartments of the cell. In the first step 5-ALA 
is produced by ALA synthetase in the mitochondria. This is the rate-limiting step in heme 
biosynthesis. 5-ALA is actively transported to the cytoplasm. After reentry into the 
mitochondrion, PpIX is produced. PpIX is the last step in the heme pathway before forming 
heme by insertion of ferrous iron by the enzyme ferrochelatase. Mitochondrial 
ferrochelatase is dependent on mitochondrial energy generation. In malignant tissue 
ferrochelatase is reduced, therefore PpIX, a strongly fluorescent and effective tissue PS 
accumulates in higher concentrations after application of 5-ALA in gliomas.(Kemmner et al. 
2008) Some more reasons for higher accumulation of PSs should be mentioned. On the 
surface of tumour cells more low-density lipoprotein (LDL) receptors are found than on the 
surface of normal cells.(Maziere, Morliere, & Santus 1991) Increased 
porphobilinogendeaminase activity in malignant glioma cells also leads to higher PpIX 
concentration. (Berkovitch-Luria et al. 2011;Greenbaum et al. 2002) At least slightly elevated 
temperature increases also the rate of biosynthesis of PpIX. 
3. Photodiagnosis and photodynamic therapy in neurosurgery 
Currently, standard treatment of glioblastoma is based on microsurgical tumour resection, 
radiation and chemotherapy. Overall prognosis of glioblastoma patients remains poor; 
therefore, new therapeutical options are necessary. Glioblastomas are diffuse infiltrating 
tumors, with growth patterns according to Scherer as follows: (i)perineuronal growth 
(perineuronal satellitosis); (ii) surface (subpial) growth; (iii) perivascular growth and (iv) 
intrafascicular growth.(Peiffer & Kleihues 1999) Due to the fact that tumor recurrence occurs 
most frequently at the resection margins, PDT of malignant glioma might be a promising 
treatment option as a local therapy. Additionally PDT might be able to reach the so called 
Guerilla cells(Claes, Idema, & Wesseling 2007), tumor cells localized in the brain adjacent to 
tumor region (BAT region) by local therapy at the end of the resection and perhaps by PDT 
stimulated anti-tumor immunity. Stimulation of anti-tumor immunity by PDT is off 
increasing relevance, an opportunity for PDT to become quite more than another local 
glioma treatment method. This topic will be discussed later in the chapter.  
In the 1970s, when lasers and optical light delivery systems became available, the 
therapeutic use of Hp maintained interest also in neurosurgery. In 1972, Diamond et al. 
studied the photodynamic effects of Hp in glioma cell cultures where addition of 10-5 M Hp 
and exposure to light caused cell death.(Diamond et al. 1972) In 1975 the same group 
investigated the photodynamic effect of Hp in vivo in Fisher rats and subcutaneous 
implanted glioma cells; the authors demonstrated a time dependent cell death of glioma 
cells increasing by time of light exposure. For clinical use of PDT in Neurosurgery mainly 
HpD and mTHPC are currently in use. 
3.1 Photodiagnosis (PD) and PDT with 5-ALA PpIX 
Introduction of 5-ALA fluorescence guided resection was a milestone in neurosurgery in 
the last fifteen years. Great contribution was done by Stummer and coworkers. 5-ALA is 
orally applied about 4 hours before surgery. Surgery is performed under operating 
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microscope, during resection the surgeon is able to switch between the white light mode 
and the fluorescent mode (blue light), where the tumour appears red fluorescent, see also 
figure 1. 
 
 
Fig. 1. Glioblastoma WHO IV at the beginning of resection in white light mode (upper row 
left) and under fluorescence mode (upper row right) after opening of the dura. Note the red 
shining PpIX fluorescence. During resection under white light conditions residual tumor 
(bottom row left) can be clearly detected under fluorescence mode (bottom row right). 
The first results of improvement of the radicality of resection by 5-ALA fluorescence guided 
surgery were published in the nineties. The results of a randomised controlled multicentre 
phase III trial performed are summerized. The German study group investigated 322 
patients enrolled by 32 investigators at 17 study centres. 161 patients were treated by 
fluorescence-guided surgery with 5-ALA, (20 mg/kg bodyweight; medac, Wedel, 
Germany), 161 were resected under conventional white light mode. In the fluorescence 
guided resection group tumor was resected completely in 65%, in the white light group 
complete tumor resection was achieved only in 36% of patients, as investigated by early 
postsurgical MRI. The difference between the groups was 29% [95% Confidence interval (CI) 
17-40], p<0.0001. Table 1 gives a short overview about the results depending to surgery (5-
ALA fluorescence guided vs. resection under white light mode).(Stummer, Pichlmeier, 
Meinel, Wiestler, Zanella, & Reulen 2006) 
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 5-ALA White light 
PFS (median) 5.1 mon. 3.6 mon. 
PFS-6 months 41.0 % 21.1 % 
SR age > 55 years 14.1 mon. 11.5 mon. 
SR age < 55 years 18 mon. 17.5 mon. 
SR 5-ALA vs. whitelight 17,9 mon. 12,9 mon 
PFS: progression free survival; SR: survival rate 
Table 1. Summary of the randomised controlled multicentre phase III trial, fluorescence-
guided surgery with 5-ALA versus white light surgery. Stummer et al. 2006 
Stratification by postoperative MRI findings showed that patients without residual contrast-
enhancing tumor had higher overall median survival than did those with residual-
enhancing tumour (17.9 months [CI 14.3-19.4] vs 12.9 months [CI 10.6-14.0]). Although in 
vivo experience demonstrated the feasibility to perform 5-ALA PDT, 5-ALA PDT is not 
established up to now in clinical practice without exceptions of some groups. Beck et al. 
2007 treated 10 patients with small and circumscribed recurrent malignant gliomas by 
implantation of up to six light diffusers with a distance of 9mm.(Beck et al. 2007) By this 
method a mean tumor volume of 5.9 cm3 could be treated. The median survival was 15 
months, without side effects in the treated patients.  
3.2 PDT in neurosurosurgery clinical studies – an overview 
Currently Kostron (2010) reviewed clinical investigations of PDT in a meta analysis, median 
survival of primary GBM with PDT was 22 months vs 15, in recurrent GBM 9 months vs. 3 
months.(Kostron 2010) A brief overview about the relevant clinical investigations in the last 
decade is given by table 2. For PDT the PSs Hpd (Photofrin®) and mTHPC (Foscan) were 
 
Author, 
Publication year 
Photosensitizer Light dose Number of 
patients 
Results 
Stylli 2005 
(Stylli et al. 2005) 
HpD 5  
mg/kg bw 
70-260 J/cm2 145 Mean survival 14.3 
mon. 
2-year survival 28% 
for newly diagnosed 
GBM 
Kostron 
2006(Kostron, 
Fiegele, & 
Akatuna 2006) 
mTHPC 0.15 
mg/kg bw 
20 J/cm2 26 Median survival 9 
mon. 
Control 3.5 mon. 
Muller 
2006(Muller & 
Wilson 2006) 
HpD 2  
mg/kg bw 
 96 Survival time 7.5 
mon., 1-year survival 
44%, 2-year survival 
22% 
Eljamel 2008 
(Eljamel 2008) 
ALA and 
Photofrin 
(HpD) 
500 J/cm2 27, 13 study 
group 14 
control group 
Tumor progression 
8.6 mon. vs. 4.8 mon. 
Table 2. Short overview - clinical investigations with PDT 
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used, the survival time was enlarged in newly and also in patients with tumor recurrence. 
Side effects of PDT were modest, including skin sensitivity against sunlight and sometimes 
increased intracranial pressure. 
Due to the small penetration depth of 5-ALA derived PpXI of 2-3mm, Eljamel et al. 
combined fluorescence guided resection and PDT.(Eljamel 2008) They used 5-ALA PpXI for 
resection and HpD for PDT. In respect to the limitation of these PSs we were encouraged to 
investigate a new PS combining both positive properties. 
4. Hypericin – high potential for PD and PDT 
Hypericin, a Naphtodianthron is a naturally occurring compound of the plant Hypericum 
perforatum, better known as St. John's wort. St. John's wort is a plant that has been used since 
the Middle Ages to treat wounds and depression. It grows bushy and has its peak season 
between May and August, see figure 2. St. John's wort contains the following active 
ingredients: essential oils, flavonoids (Biapigenin, hyperoside, Isoquercitin, rutin), tannins, 
glycosides, resins, Naphtodianthrone (hypericin, Pseudohyericin) and phloroglucinol 
(hyperforin). In 1942 by Pace a pronounced sensitization of the skin by light for grazing 
animals taken St. John's wort containing feed was described. The changes in the skin were 
reversible after the animals were protected from sun exposure. The phenomenon was 
described as hypericism.(Pace 1942) Hypericin is a lipophilic molecule that is incorporated into 
the phospholipid bilayer of cell membranes and has already in the dark versatile 
pharmacological activities. These include antiviral, anticancer and antiangiogenic properties. 
Takahashi et al. could show an inhibitory effect on proteinkinase C, which is involved in cell 
proliferation.(Takahashi et al., 1989) Malignant gliomas have, compared to glial cells, a high 
proteinkinase C activity.(Couldwell et al. 1991) Hypericin has excellent properties as a PS. It 
has a high triplet quantum yield and a high efficiency in the formation of ROS.(Diwu & Lown 
1993;Ehrenberg, Anderson, & Foote 1998;Hadjur et al. 1996) 
The excessive production of the so called ROS leads to oxidative stress to many 
biomolecules, e.g. proteins, causing cell death by induction of apoptosis, necrosis or 
autophagy associated cell death.(Buytaert, Dewaele, & Agostinis 2007) 
 
 
Fig. 2. St. John’s wort, also known as Hypericum perforatum;  
[www.awl.ch/heilpflanzen/hypericum-perforatum/index.htm]. 
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4.1 Hypericin differentiating neurons and glioma cell lines in vitro  
For selective PDT it would be advantageous when the PS enriches in the malignant cells 
more compared to neurons or glial cells. In 2005 we investigated eight human glioma cell 
lines (L; LN-18,LN-229, U87MG, U373MG, D247MG, U251MG, U251MG,T98G) and twelve 
primary human glioma cell cultures (P) and compared the hypericin uptake with human 
astrocytes (AC; SV-FHAS) and cerebellar granule neurons (N) prepared from 8-day-old 
Sprague-Dawley rat pups (Charles River, Sulzfeld, Germany). Long term glioma cell lines 
and primary human glioma cell cultures showed significant higher hypericin uptake 
compared to neurons. Hypericin uptake in astrocytes was higher compared to glioma cells 
and to neurons.(Ritz et al. 2005) Another investigation done by fluorescence microscopy 
showed that hypericin was predominately localized in the glial envelope surrounding the 
neuron in a model with crayfish neuron and surrounding glia. Uzdensky et al. found a 
minor fraction of hypericin in the neuron compared to the glia in this model.(Uzdensky et 
al. 2003) 
4.2 Subcellular distribution of hypericin 
Predominantly perinuclear localization of hypericinis is in common concordance.(Uzdensky 
et al. 2001) The more detailed description of subcellular distribution of hypericin is not 
uniform. Due to the very short life span of the singlet-oxygen for cytotoxic reactions, the 
subcellular distribution of hypericin is off interest to understand PDT mechanisms in more 
detail. Many investigators studied in different cultured cell lines with different methods the 
subcellular hypericin localisation. According to our studies hypericin enriches particularly 
in the endoplasmatic reticulum (ER) and the Golgi apparatus (GA) in U37MG glioblastoma 
cells after incubation with noncytotoxic hypericin (1µM, 2h incubation time). ER is 
predominantly found in the perinuclear region while the GA is more distant to the nucleus, 
see figure 3.(Ritz et al. 2007b;Ritz et al. 2008) 
 
 
Fig. 3a. Long-term glioblastoma, incubated with 20µM Hypericin. Note the perinuclear 
granular enrichment. 
www.intechopen.com
 
Advances in the Biology, Imaging and Therapies for Glioblastoma 
 
190 
  
 
 
 
 
Fig. 3b. Fluorescence microscopic images of U373 MG glioblastoma cells, co stained with 
ER-Tracker (2 M/20 min) and Hypericin (1µM/2h). (A) staining for ER, (B) hypericin 
fluorescence.  (C) demonstrates the costaining image. C-I original image, C-II after image 
processing.  
4.3 Kinetic of intracellular accumulation of hypericin 
The cellular accumulation of hypericin in glioma cell culture is time and concentration 
dependent. Short incubation times of 2 h lead to saturation up to 5µM hypericin, higher 
concentrations do not increase hypericin accumulation. Cellular hypericin uptake is 
subjected by active temperature dependent transport mechanism, although details are not 
clear at all (Fig. 4).(Ritz, Wein, Dietz, Schenk, Roser, Tatagiba, & Strauss 2007b) 
C-I
C-IIC 20 µm 
A 20 µm B 20 µm 
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Fig. 4a. Incubation concentration dependent hypericin uptake in U373 MG cells. Cells were 
incubated for 2 hours; up to 5 µM cellular fluorescence increased. No further increase was 
found at higher incubation concentrations. 
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Fig. 4b. Cellular accumulation of hypericin in U373MG glioblastoma cells (incubation 
concentration 2.5µM) dependent on incubation temperature [(4°C for 2h and subsequently 
37°C for further 2 h (●) vs. 37°C for 4h (o)] measured by flow cytometry. 
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4.4 Photodynamic therapy with hypericin in glioma 
Hypericin exhibits high phototoxicity combined with weak to negligible dark cytotoxicity, 
as reported previously.(Ritz et al. 2007a) Optimal illumination wavelength for PDT is at 
595nm. In our in vitro studies on glioma cells, a dosis of 0.15-0.2 J/cm2 resulted in cell 
survival to 50% (ID50-value); after exposure to 0.4 J/cm2 cell survival was reduced to about 
10% as compared to non-illuminated controls. In comparison other investigators applied 
light doses between 2 J/cm2 (ID50 in U373 MG) up to 15J/cm2 for 5-ALA PDT.(Blake & 
Curnow 2010) 
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Fig. 5. Phototoxicity of hypericin in T98G cell line. Phototoxicity depends on incubation 
concentration (incubation time of 2h) and light dose. Cells were incubated with 0.5 µM (●) 
1.5 µM (♦) and 2.5 µM (▲). Illumination was performed at 595 nm, light was delivered at 5-
10 mW/cm2. Cell viability is given on the ordinate.  
4.5 Tumor selectivity of hypericin in vivo 
Basical for a successful clinical application of hypericin for fluorescence guided resection 
and PDT is a selective enrichment in tumor tissue without enrichment in normal brain 
tissue. For this we evaluated in a C6 rat glioma model selective hypericin accumulation in 
tumor tissue compared to BAT zone and normal brain tissue. By these experiments it could 
be demonstrated that ratios of hypericin in rat glioma compared to BAT and normal brain 
tissue were 19.8:2.5:1 (Fig. 6).(Noell et al. 2011) Hypericin was found in a high concentration 
in tumor tissue, BAT zone was also enriched by hypericin in contrast to normal brain tissue 
were no hypericin was found. 
Our first clinical results demonstrated also a high potential of hypericin for fluorescence 
guided surgery in malignant glioma, data are submitted for publication.  
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Fig. 6. Cryosections of the C6 glioma in rat brain. Contralateral hemisphere without tumor 
(left), BAT zone (middle) and tumor (right). Selective hypericin accumulation (red 
fluorescence) in the tumor and tumor infiltration zone co-stained with DAPI (blue) is 
demonstrated in the upper row. Corresponding sections stained by hematotoxylin and eosin 
(lower row).  
5. Photodynamic therapy and anti-tumor immunity – A chance for PDT to be 
more than a local cancer therapy? 
In malignant brain tumors standard therapy is based on surgery, radiation and 
chemotherapy. The prognosis of patients is still dismal. There is no doubt about the 
necessitiy of other treatment options. As mentioned in this chapter PDT represents an 
interesting therapy option in addition to the modern therapeutical strategies described in 
this book. At the first moment PDT seems only as one additional tool of local tumor 
treatment, with all advantages, e.g. low costs compared to modern biotechnical products, 
selective and repetitive application. Therapy resistancy has been seldom observed. PDT is 
able to occluse tumor associated vessels, mainly PDT induces apoptosis and necrosis, also 
autophagy plays a role. Great hope lies in the modulation of immune system by PDT. 
Fluorescence guided tumor resection is able to eradicate tumor locally. In combination with 
www.intechopen.com
 
Advances in the Biology, Imaging and Therapies for Glioblastoma 
 
194 
induced systemic anti-tumor immune reactions distant tumor cells, e.g. Guerilla cells could 
be treated. Several mechanisms contribute therefore. Cells killed by PDT produce signals, 
increasing antigen presentation by dendric cells (DCs) and recruit antigen-specific cytotoxic 
T lymphocytes (CTLs).(Mroz et al. 2011) 
Great importance is also given to so called damage-associated molecular patterns (DAMPs). 
DAMPs are intracellular molecules in living cells, exposed by sudden cell damage as 
initialized for example by PDT. Up to date it is generally accepted that PDT activates the 
immune system. Complete understanding of the processes and how to influence them for 
improvement the immune responses is mandatory and could be advanced by closer 
cooperation of researchers in PDT and immunology.  
6. Conclusion and future directions 
PDT for malignant gliomas is an interesting additional therapeutic tool with low side effects. 
By fundamentally distinct mechanisms compared to radiochemotherapy PDT also offers 
new opportunities for patients with tumor relapse. Hypericin seems to be a quite effective 
fluorescence marker for the detection of glioma. Since hypericin exhibits excellent 
photosensitizing properties, as demenostrated in detail in vitro, it might also be a promising 
PS in glioma therapy. Further in vivo investigations will proof this hypothesis in future. Due 
to high induction of apoptosis by hypericin mediated PDT, further investigations should 
focus on anti-tumor immunity by hypericin PDT, a chance to be more than only a local 
therapeutic tool. 
7. References 
Auler, H. & Banzer, G. Untersuchungen über die Rolle der Porphyrine bei 
geschwulstkranken Menschen und Tieren. Z Krebsforsch 53[65], 68. 1942.  
Ref Type: Journal (Full) 
Beck, T. J., Kreth, F. W., Beyer, W., Mehrkens, J. H., Obermeier, A., Stepp, H., Stummer, W., 
& Baumgartner, R. 2007, "Interstitial photodynamic therapy of nonresectable 
malignant glioma recurrences using 5-aminolevulinic acid induced protoporphyrin 
IX", Lasers Surg.Med., vol. 39, no. 5, pp. 386-393. 
Berkovitch-Luria, G., Weitman, M., Nudelman, A., Rephaeli, A., & Malik, Z. 2011, 
"Multifunctional 5-aminolevulinic acid prodrugs activating diverse cell-death 
pathways 1", Invest New Drugs. 
Blake, E. & Curnow, A. 2010, "The hydroxypyridinone iron chelator CP94 can enhance PpIX-
induced PDT of cultured human glioma cells 1", Photochem.Photobiol., vol. 86, no. 5, 
pp. 1154-1160. 
Buytaert, E., Dewaele, M., & Agostinis, P. 2007, "Molecular effectors of multiple cell death 
pathways initiated by photodynamic therapy 2", Biochim.Biophys.Acta, vol. 1776, no. 
1, pp. 86-107. 
Claes, A., Idema, A. J., & Wesseling, P. 2007, "Diffuse glioma growth: a guerilla war", Acta 
Neuropathol., vol. 114, no. 5, pp. 443-458. 
Couldwell, W. T., Uhm, J. H., Antel, J. P., & Yong, V. W. 1991, "Enhanced protein kinase C 
activity correlates with the growth rate of malignant gliomas in vitro 
www.intechopen.com
 
Visualization and Photodynamic Therapy in Malignant Glioma - An Overview and Perspectives 
 
195 
41", Neurosurgery, vol. 29, no. 6, pp. 880-886. 
Diamond, I., Granelli, S. G., McDonagh, A. F., Nielsen, S., Wilson, C. B., & Jaenicke, R. 1972, 
"Photodynamic therapy of malignant tumours 2", Lancet, vol. 2, no. 7788, pp. 1175-
1177. 
Diwu, Z. & Lown, J. W. 1993, "Photosensitization with anticancer agents. 17. EPR studies 
of photodynamic action of hypericin: formation of semiquinone radical and 
activated oxygen species on illumination", Free Radic.Biol.Med., vol. 14, no. 2, pp. 
209-215. 
Dougherty, T. J. Photoradiation therapy. Abstracts of the American Chemical Society 
Meeting 1973, Chicago, II.  1973.  Ref Type: Abstract 
Dougherty, T. J., Gomer, C. J., Henderson, B. W., Jori, G., Kessel, D., Korbelik, M., Moan, J., 
& Peng, Q. 1998a, "Photodynamic therapy", J.Natl.Cancer Inst., vol. 90, no. 12, pp. 
889-905. 
Dougherty, T. J., Gomer, C. J., Henderson, B. W., Jori, G., Kessel, D., Korbelik, M., Moan, J., 
& Peng, Q. 1998b, "Photodynamic therapy 4", J Natl.Cancer Inst., vol. 90, no. 12, pp. 
889-905. 
Dougherty, T. J., Kaufman, J. E., Goldfarb, A., Weishaupt, K. R., Boyle, D., & Mittleman, A. 
1978, "Photoradiation therapy for the treatment of malignant tumors 
14", Cancer Res., vol. 38, no. 8, pp. 2628-2635. 
Dreyer, G. Lichtbehandlung nach Sensibilisierung. Dermatol Z 10, 6. 1903.  
Ehrenberg, B., Anderson, J. L., & Foote, C. S. 1998, "Kinetics and yield of singlet oxygen 
photosensitized by hypericin in organic and biological media", Photochem.Photobiol., 
vol. 68, no. 2, pp. 135-140. 
Eljamel, M. S. 2008, "Brain photodiagnosis (PD), fluorescence guided resection (FGR) and 
photodynamic therapy (PDT): past, present and future", Photodiagnosis. 
Photodyn.Ther., vol. 5, no. 1, pp. 29-35. 
Figge, H. J., Weiland, G. S., & Manganiello, L. J. Cancer detection and therapy, affinity of 
neoplastic, embryonic, and traumatized tissues for porphyrins and 
metalloporphyrins. Proc Soc Exp Biol Med 68, 640-641. 1948. 
Greenbaum, L., Gozlan, Y., Schwartz, D., Katcoff, D. J., & Malik, Z. 2002, "Nuclear 
distribution of porphobilinogen deaminase (PBGD) in glioma cells: a regulatory 
role in cancer transformation? 4", Br.J Cancer, vol. 86, no. 6, pp. 1006-1011. 
Hadjur, C., Richard, M. J., Parat, M. O., Jardon, P., & Favier, A. 1996, "Photodynamic effects 
of hypericin on lipid peroxidation and antioxidant status in melanoma cells", 
Photochem.Photobiol., vol. 64, no. 2, pp. 375-381. 
Hausmann, W. Die sensibilisierende Wirkung des Hämatoporphyrins. Biochem Z 30, 276-
316. 1911. 
Juzeniene, A., Peng, Q., & Moan, J. 2007, "Milestones in the development of photodynamic 
therapy and fluorescence diagnosis 12", Photochem.Photobiol.Sci., vol. 6, no. 12, pp. 
1234-1245. 
Kemmner, W., Wan, K., Ruttinger, S., Ebert, B., Macdonald, R., Klamm, U., & Moesta, K. T. 
2008, "Silencing of human ferrochelatase causes abundant protoporphyrin-IX 
accumulation in colon cancer 1", FASEB J, vol. 22, no. 2, pp. 500-509. 
www.intechopen.com
 
Advances in the Biology, Imaging and Therapies for Glioblastoma 
 
196 
Kennedy, J. C., Pottier, R. H., & Pross, D. C. 1990, "Photodynamic therapy with endogenous 
protoporphyrin IX: basic principles and present clinical experience 
16", J Photochem.Photobiol.B, vol. 6, no. 1-2, pp. 143-148. 
Kostron, H. 2010, "Photodynamic diagnosis and therapy and the brain 
4", Methods Mol.Biol, vol. 635, pp. 261-280. 
Kostron, H., Fiegele, T., & Akatuna, E. Combination of FOSCAN mediated fluorescence 
guided resection and photodynamic treatment as new therpeutic concept for 
malignant brain tumors. Med Las Appl 21, 285-290. 2006. 
Kostron, H., Obwegeser, A., & Jakober, R. 1996, "Photodynamic therapy in neurosurgery: a 
review 19", J Photochem.Photobiol.B, vol. 36, no. 2, pp. 157-168. 
Ledoux-Lebards, C. Annales de l'Institut Pasteur 16, 593. 1902. 
Lipson, L., Baldes, E. J., & Olsen, A. M. A further evaluation of the use of hematoporphyrin 
derivative as a new aid for the endoscopic detection of malignan disease. Dis Chest 
46, 676-679. 1964. 
Malik, Z. & Lugaci, H. 1987, "Destruction of erythroleukaemic cells by photoactivation of 
endogenous porphyrins 2", Br.J Cancer, vol. 56, no. 5, pp. 589-595. 
Maziere, J. C., Morliere, P., & Santus, R. 1991, "The role of the low density lipoprotein 
receptor pathway in the delivery of lipophilic photosensitizers in the photodynamic 
therapy of tumours 11", J Photochem.Photobiol.B, vol. 8, no. 4, pp. 351-360. 
Meyer-Betz, F. Untersuchungen über die biologische (photodynamische) Wirkung des 
Hämatoporphyrins und anderer Derivate des Blut- und Gallenfarbstoffes. Dtsch 
Arch Klin Med 112, 476-503. 1913.  
Mroz, P., Hashmi, J. T., Huang, Y. Y., Lange, N., & Hamblin, M. R. 2011, "Stimulation of anti-
tumor immunity by photodynamic therapy 4", Expert.Rev.Clin.Immunol., vol. 7, no. 
1, pp. 75-91. 
Muller, P. J. & Wilson, B. C. Photodynamic therapy of brain tumors-A work in progress. 
Lasers Surg.Med. 38, 384-389. 2006. 
Neisser, A. & Halberstaedtter, L. Mitteilung über Lichtbehandlung nach Dreyer. Dtsch Med 
Wochenschr 8, 265-269. 1904. 
Noell, S., Mayer, D., Strauss, W. S., Tatagiba, M. S., & Ritz, R. 2011, "Selective enrichment of 
hypericin in malignant glioma: Pioneering in vivo results 
2", Int.J Oncol., vol. 38, no. 5, pp. 1343-1348. 
Obwegeser, A., Jakober, R., & Kostron, H. 1998, "Uptake and kinetics of 14C-labelled meta-
tetrahydroxyphenylchlorin and 5-aminolaevulinic acid in the C6 rat glioma model 
14", Br.J Cancer, vol. 78, no. 6, pp. 733-738. 
Pace, N. 1942, "The etiology of hypericism, a photosensitivity produced by St. Johnswort", 
Am J Physiol, vol. 136, pp. 650-565. 
Peiffer, J. & Kleihues, P. 1999, "Hans-Joachim Scherer (1906-1945), pioneer in glioma research 
11", Brain Pathol., vol. 9, no. 2, pp. 241-245. 
Policard, A. Etude sur les aspects offerts pa des tumeurs expérimentales examinées à la 
lumière de Wood. C R Soc Biol 91, 1423-1424. 1924. 
Raab, O. Über die Wirkung fluoreszierender Stoffe auf Infusoria. Z Biol 39, 524-566.  
1900. 
www.intechopen.com
 
Visualization and Photodynamic Therapy in Malignant Glioma - An Overview and Perspectives 
 
197 
Ritz, R., Muller, M., Weller, M., Dietz, K., Kuci, S., Roser, F., & Tatagiba, M. 2005, "Hypericin: 
a promising fluorescence marker for differentiating between glioblastoma and 
neurons in vitro", Int.J.Oncol., vol. 27, no. 6, pp. 1543-1549. 
Ritz, R., Roser, F., Radomski, N., Strauss, W. S., Tatagiba, M., & Gharabaghi, A. 2008, 
"Subcellular colocalization of hypericin with respect to endoplasmic reticulum and 
Golgi apparatus in glioblastoma cells", Anticancer Res., vol. 28, no. 4B, pp. 2033-
2038. 
Ritz, R., Wein, H. T., Dietz, K., Schenk, M., Roser, F., Tatagiba, M., & Strauss, W. S. 2007a, 
"Photodynamic therapy of malignant glioma with hypericin: comprehensive in 
vitro study in human glioblastoma cell lines", Int.J Oncol., vol. 30, no. 3, pp. 659-
667. 
Ritz, R., Wein, H. T., Dietz, K., Schenk, M., Roser, F., Tatagiba, M., & Strauss, W. S. 2007b, 
"Photodynamic therapy of malignant glioma with hypericin: comprehensive in 
vitro study in human glioblastoma cell lines", Int.J.Oncol., vol. 30, no. 3, pp. 659-
667. 
Schwartz, S., Absolon, K., & Vermund, H. Some relationships of porphyrins, x-rays and 
tumors. Med Bull 27, 7-13. 1955. 
Scott, J. The Biosynthesis of Porphyrins and Porphyrin metabolism. Ciba foundation 
Symposium, London, Churchill , 43. 1955. 
Stummer, W., Novotny, A., Stepp, H., Goetz, C., Bise, K., & Reulen, H. J. 2000, 
"Fluorescence-guided resection of glioblastoma multiforme by using 5-
aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive 
patients", J.Neurosurg., vol. 93, no. 6, pp. 1003-1013. 
Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., & Reulen, H. J. 2006, 
"Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant 
glioma: a randomised controlled multicentre phase III trial", Lancet Oncol., vol. 7, 
no. 5, pp. 392-401. 
Stummer, W., Reulen, H. J., Meinel, T., Pichlmeier, U., Schumacher, W., Tonn, J. C., Rohde, 
V., Oppel, F., Turowski, B., Woiciechowsky, C., Franz, K., & Pietsch, T. 2008, 
"Extent of resection and survival in glioblastoma multiforme: identification of and 
adjustment for bias", Neurosurgery, vol. 62, no. 3, pp. 564-576. 
Stylli, S.S., Kaye, A.H., MacGregor, L., Howes, M., Rajendra, P.J. 2005, "Photodynamic 
therapy of high grade glioma - long term survival.” Clin  Neurosci., vol. 12no. 4, 
pp. 389-98. 
Takahashi, I., Nakanishi, S., Kobayashi, E., Nakano, H., Suzuki, K., & Tamaoki, T. 1989, 
"Hypericin and pseudohypericin specifically inhibit protein kinase C: possible 
relation to their antiretroviral activity", Biochem.Biophys.Res.Commun., vol. 165, no. 3, 
pp. 1207-1212. 
Tappeiner, H. v. & Jodlbauer, A. Über die Wirkung der photodynamischen 
(fluoreszierenden) Stoffe auf Infusorien. Dtsch Arch Klin Med 80, 427-487. 1904. 
Uzdensky, A. B., Bragin, D. E., Kolosov, M. S., Kubin, A., Loew, H. G., & Moan, J. 2003, 
"Photodynamic effect of hypericin and a water-soluble derivative on isolated 
crayfish neuron and surrounding glial cells", J.Photochem.Photobiol.B, vol. 72, no. 1-3, 
pp. 27-33. 
www.intechopen.com
 
Advances in the Biology, Imaging and Therapies for Glioblastoma 
 
198 
Uzdensky, A. B., Ma, L. W., Iani, V., Hjortland, G. O., Steen, H. B., & Moan, J. 2001, 
"Intracellular localisation of hypericin in human glioblastoma and carcinoma cell 
lines", Lasers Med.Sci., vol. 16, no. 4, pp. 276-283. 
www.intechopen.com
Advances in the Biology, Imaging and Therapies for Glioblastoma
Edited by Prof. Clark Chen
ISBN 978-953-307-284-5
Hard cover, 424 pages
Publisher InTech
Published online 09, November, 2011
Published in print edition November, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book is intended for physicians and scientists with interest in glioblastoma biology, imaging and therapy.
Select topics in DNA repair are presented here to demonstrate novel paradigms as they relate to therapeutic
strategies. The book should serve as a supplementary text in courses and seminars as well as a general
reference.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Rainer Ritz (2011). Visualization and Photodynamic Therapy in Malignant Glioma - An Overview and
Perspectives, Advances in the Biology, Imaging and Therapies for Glioblastoma, Prof. Clark Chen (Ed.), ISBN:
978-953-307-284-5, InTech, Available from: http://www.intechopen.com/books/advances-in-the-biology-
imaging-and-therapies-for-glioblastoma/visualization-and-photodynamic-therapy-in-malignant-glioma-an-
overview-and-perspectives
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
